Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
130 stopped studies mapped to Malignant Fallopian Tube Neoplasm and descendants · 88% state a reason
Over the 130 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04510584 | Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer | Phase 2 | withdrawn | Aug 12, 2020 | University Health Network, Toronto | 19 patients screenfailed, stopping recruitment before first patient enrollment to analyze pilot… | Enrollment / accrual |
| NCT05368506 | ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian… | Early Phase 1 | withdrawn | May 10, 2022 | OHSU Knight Cancer Institute | PI discretion | Other (stated, no rule matched) |
| NCT04368130 | SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care(SIGNAL) | N/A | withdrawn | Apr 29, 2020 | Dana-Farber Cancer Institute | The anomaly detection system is still under development and is not ready to test. | Other (stated, no rule matched) |
| NCT00373217 | Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing… | Phase 2 | terminated | Sep 7, 2006 | Craig L Slingluff, Jr | Slow enrollment rate. | Enrollment / accrual |
| NCT03924245 | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant… | Phase 1 | terminated | Apr 23, 2019 | Vanderbilt-Ingram Cancer Center | Change in participant landscape and other treatment availability | Other (stated, no rule matched) |
| NCT03029611 | IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV… | Phase 2 | terminated | Jan 24, 2017 | University of Washington | Terminated due to lack of funding | Funding |
| NCT03905902 | DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary…(VITALIA) | Phase 3 | withdrawn | Apr 8, 2019 | SOTIO a.s. | Company decision | Sponsor / business decision |
| NCT01312389 | A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian,… | Phase 1 / Phase 2 | terminated | Mar 10, 2011 | Abramson Cancer Center at Penn Medicine | Did not meet criteria laid out in Phase 1 to continue to Phase 2 | Other (stated, no rule matched) |
| NCT01035658 | Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary… | Phase 1 / Phase 2 | terminated | Dec 21, 2009 | SCRI Development Innovations, LLC | Based on analyses in Phase I, the study did not advance to Phase II. | Other (stated, no rule matched) |
| NCT03607955 | Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial… | Phase 1 | withdrawn | Jul 31, 2018 | Washington University School of Medicine | Trial may move forward as an NCI-sponsored trial and not an investigator initiated trial. | Investigator |
| NCT03608618 | Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian… | Phase 1 | terminated | Aug 1, 2018 | MaxCyte, Inc. | Sponsor shift in focus | Other (stated, no rule matched) |
| NCT00582205 | Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and… | Phase 2 | terminated | Dec 28, 2007 | University of Oklahoma | Study completed per investigator. | Investigator |
| NCT04498520 | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic… | Phase 1 | withdrawn | Aug 4, 2020 | Pamela Munster | Funding | Funding |
| NCT03902379 | Web-Based Coping and Communication Skills Intervention in Improving Psychological… | N/A | withdrawn | Apr 4, 2019 | Rutgers, The State University of New Jersey | The study was never initiated, no patients were enrolled. It has been closed with the IRB. | Enrollment / accrual |
| NCT03312114 | Anti-PD-L1 and SAbR for Ovarian Cancer | Phase 2 | terminated | Oct 17, 2017 | University of Texas Southwestern Medical Center | low accrual | Enrollment / accrual |
| NCT01312376 | Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer | Phase 1 | terminated | Mar 10, 2011 | Abramson Cancer Center at Penn Medicine | not stated | Not stated |
| NCT02452775 | Autologous OC-L Vaccine and Ovarian Cancer | Phase 1 | terminated | May 25, 2015 | Abramson Cancer Center at Penn Medicine | not stated | Not stated |
| NCT02487849 | HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive…(HIPEC) | Phase 2 | withdrawn | Jul 2, 2015 | Krankenhaus Barmherzige Schwestern Linz | actually limited personnel ressources | Other (stated, no rule matched) |
| NCT00693342 | Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial… | Phase 3 | withdrawn | Jun 9, 2008 | Gynecologic Oncology Group | Never opened to accrual, a GOG working number, not developed into a clinical trial. | Enrollment / accrual |
| NCT01766622 | 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant | Phase 2 | withdrawn | Jan 11, 2013 | National Institutes of Health Clinical Center (CC) | not stated | Not stated |
| NCT02661815 | A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer | Phase 1 | terminated | Jan 25, 2016 | Dana-Farber Cancer Institute | Company decided not to move forward with further accrual. | Enrollment / accrual |
| NCT02012192 | GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer | Phase 1 / Phase 2 | terminated | Dec 16, 2013 | Medical University Innsbruck | production of IMP has stopped | Other (stated, no rule matched) |
| NCT01144442 | WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First… | N/A | terminated | Jun 15, 2010 | Masonic Cancer Center, University of Minnesota | PI Request | Other (stated, no rule matched) |
| NCT02948101 | PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial… | Phase 2 | withdrawn | Oct 28, 2016 | M.D. Anderson Cancer Center | PI's request | Other (stated, no rule matched) |
| NCT02050009 | Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent… | Phase 1 | withdrawn | Jan 30, 2014 | Fox Chase Cancer Center | study was never opened to accrual | Enrollment / accrual |
| NCT01083537 | Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With… | Phase 1 / Phase 2 | terminated | Mar 9, 2010 | University Health Network, Toronto | Slow accrual | Enrollment / accrual |
| NCT02530606 | Photoacoustic Imaging in Detecting Ovarian or Fallopian Tube Cancer | N/A | withdrawn | Aug 21, 2015 | Stanford University | Efficacy | Efficacy / futility |
| NCT00005645 | ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not… | Phase 2 | withdrawn | May 26, 2004 | Genzyme, a Sanofi Company | not stated | Not stated |
| NCT00322881 | Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or… | Phase 2 | terminated | May 8, 2006 | Dana-Farber Cancer Institute | Early closure based on audit by study investigators after 3 patients died on study. | Other (stated, no rule matched) |
| NCT00910000 | Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive… | Phase 1 / Phase 2 | terminated | May 29, 2009 | Dana-Farber Cancer Institute | Terminated due to unacceptable toxicity | Safety / toxicity |
| NCT02872519 | PET Imaging of Ovarian Carcinoma With 18F-FSPG | Early Phase 1 | withdrawn | Aug 19, 2016 | Vanderbilt-Ingram Cancer Center | No funding | Funding |
| NCT00866723 | Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube… | Phase 2 | terminated | Mar 20, 2009 | Beth Israel Deaconess Medical Center | Recruitment has been terminated prematurely because of poor enrollment. | Enrollment / accrual |
| NCT00899093 | YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian… | — | terminated | May 12, 2009 | Gynecologic Oncology Group | not stated | Not stated |
| NCT01275664 | Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients… | N/A | terminated | Jan 12, 2011 | Gynecologic Oncology Group | Study terminated due to no patient population available | Other (stated, no rule matched) |
| NCT02833506 | Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian… | Phase 1 | withdrawn | Jul 14, 2016 | Roswell Park Cancer Institute | production of adjuvant to be used with vaccine was discontinued by sponsor | Other (stated, no rule matched) |
| NCT01773889 | A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage… | Phase 2 | terminated | Jan 23, 2013 | The University of Texas Health Science Center at San Antonio | Lack of funding | Funding |
| NCT00408070 | Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary… | Phase 2 | terminated | Dec 6, 2006 | UConn Health | Did not meet accrual goals. | Enrollment / accrual |
| NCT01936974 | (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and…(PGA) | Phase 2 | terminated | Sep 6, 2013 | Western Regional Medical Center | PI Decision | Other (stated, no rule matched) |
| NCT00303888 | Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced… | Phase 1 | terminated | Mar 17, 2006 | Yale University | not stated | Not stated |
| NCT00574951 | AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer,… | Phase 2 | terminated | Dec 17, 2007 | Gynecologic Oncology Group | Study was stopped for severe toxicity causing concern for patients | Safety / toxicity |
| NCT00331422 | Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian… | Phase 2 | terminated | May 31, 2006 | Masonic Cancer Center, University of Minnesota | Study was terminated due to lack of available funding. | Funding |
| NCT00652899 | Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian… | Phase 2 | terminated | Apr 4, 2008 | Masonic Cancer Center, University of Minnesota | Withdrawn due to toxicity | Safety / toxicity |
| NCT00903630 | Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial… | Phase 1 / Phase 2 | terminated | May 18, 2009 | Masonic Cancer Center, University of Minnesota | lack of funding | Funding |
| NCT01281254 | AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) | Phase 3 | terminated | Jan 21, 2011 | Amgen | Closure of long term follow up (LTFU) and study earlier than previously outlined in the protocol as… | Other (stated, no rule matched) |
| NCT00287859 | Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary… | Phase 1 | terminated | Feb 7, 2006 | Masonic Cancer Center, University of Minnesota | Withdrawn due to low accrual | Enrollment / accrual |
| NCT02278783 | Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and… | Phase 2 | terminated | Oct 30, 2014 | University of Utah | Slow Accrual | Enrollment / accrual |
| NCT00354601 | Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian… | Phase 2 | terminated | Jul 20, 2006 | Wake Forest University Health Sciences | funding withdrawn | Funding |
| NCT00551265 | Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage… | N/A | withdrawn | Oct 30, 2007 | Gynecologic Oncology Group | not stated | Not stated |
| NCT01972516 | Tivozanib As Maintenance Therapy In GYN | Phase 2 | terminated | Oct 30, 2013 | Dana-Farber Cancer Institute | due to slow accrual | Enrollment / accrual |
| NCT01659554 | A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by…(HIPEC) | Phase 2 | terminated | Aug 8, 2012 | Columbia University | Principal Investigator left institution | Investigator |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jun 6, 2023source: clinicaltrials